Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the company’s control, including the risks described from time to time in its SEC filings. The company’s results may differ materially from those projections. These statements involve material risks and uncertainties that could cause actual results or events to differ materially. Accordingly, you should not place undue reliance on these statements. I encourage you to review the company’s filings with the SEC ...

DarioHealth logo DarioHealth is an AI-Powered Digital Therapeutics Play DarioHealth (NASDAQ:DRIO) executives highlighted record commercial momentum and continued cost reductions on the company’s fourth-quarter and year-end 2025 earnings call, while also addressing the revenue impact of a single legacy customer non-renewal and outlining expectations for accelerating growth through 2026. Record new agreements, but full-year revenue declined Chief Executive Officer Erez Raphael said 2025 was the compa ...

DarioHealth (NasdaqCM:DRIO) Q4 2025 Earnings call March 19, 2026 08:30 AM ET Speaker3Good morning, ladies and gentlemen, and welcome to the DarioHealth fourth quarter and year-end 2025 results conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, March 19, 2026. I would now li ...

分组1 - DarioHealth Corp. reported a quarterly loss of $0.8 per share, which was better than the Zacks Consensus Estimate of a loss of $1.57, representing an earnings surprise of +48.88% [1] - The company posted revenues of $5.23 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.17%, but down from $7.6 million year-over-year [2] - DarioHealth shares have declined approximately 21.5% since the beginning of the year, contrasting with the S&P 500's decline of 3.2% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.67 on revenues of $5.1 million, and for the current fiscal year, it is -$3.43 on revenues of $26.8 million [7] - The Zacks Industry Rank for Medical - Instruments is in the top 36% of over 250 Zacks industries, indicating that the industry is performing relatively well [8]

Core Insights - DarioHealth reported its strongest commercial year in 2025, signing 85 new agreements and expecting $12.9 million in annual recurring revenue (ARR) to convert to revenue in 2026 and 2027 [2][4] - The company experienced a revenue decline due to the loss of a legacy client from the Twill acquisition, but fourth-quarter revenue showed sequential growth [2][4] - DarioHealth's commercial pipeline has expanded to $122 million, indicating strong near-term visibility for growth [2][4] Financial Performance - Full-year revenue for 2025 was $22.4 million, down from $27.0 million in 2024, primarily due to a scope change and nonrenewal from a legacy client [4][18] - Fourth-quarter revenue increased to $5.2 million from $5.0 million in the previous quarter, marking a return to growth [4][10] - Gross margins improved to 57% in 2025 from 49% in 2024, with non-GAAP gross margins sustaining at 80% for two years [4][19] Operating Expenses and Losses - Total operating expenses for 2025 decreased by 31% to $49.3 million compared to $71.0 million in 2024, driven by operational efficiencies and post-merger integration [4][20] - The operating loss for 2025 was $36.7 million, a 37% reduction from $57.7 million in 2024 [4][22] - Non-GAAP operating loss is expected to decrease by approximately 30% in 2026, with a target of cash flow breakeven by mid-2027 [9] Growth Drivers - DarioHealth's multi-condition platform allows for greater member reach and enrollment, contributing to revenue growth [7] - The company has access to approximately 116 million covered lives through channel partnerships, enhancing its market reach without proportional increases in sales infrastructure [7] - Increased demand for Dario's musculoskeletal product in the B2C market saw a 36% growth in Q4 2025, with expectations for continued international expansion [4][6] Strategic Positioning - DarioHealth's ownership of its entire vertical value chain, including clinical data, is seen as a competitive advantage [3] - The launch of AI-driven solutions, backed by 13 billion real-world data points, reinforces Dario's leadership in digital health [5] - The company emphasizes delivering measurable clinical and financial results to payers and employers, addressing rising healthcare costs [6]

Business Model and Growth - DarioHealth has signed over 100 total contracts as of now, indicating rapid scaling of its B2B2C model[398]. - The company has acquired multiple subsidiaries, including Upright and Twill, to enhance its health management platform[398][401]. - DarioHealth's revenue is derived from both consumer and commercial segments, with services including digital therapeutics and clinical coaching[411][413]. - DarioHealth's AI tools leverage data from over 150,000 members to improve user engagement and health outcomes[398]. - The company aims to transform healthcare by providing a comprehensive health platform that integrates hardware, AI, and behavioral coaching[396]. - DarioHealth's solutions currently address diabetes, hypertension, pre-diabetes, musculoskeletal conditions, and behavioral health[398]. - The company emphasizes user engagement as a critical factor for achieving sustained behavior change and improved health outcomes[397]. Financial Performance - Revenues for the year ended December 31, 2025, amounted to $22,359, a decrease from $27,040 in 2024, primarily due to the non-renewal of a customer acquired through the Twill acquisition[424]. - Gross profit for the year ended December 31, 2025, was $12,665, representing 56.6% of revenues, compared to $13,267 or 49.1% of revenues in 2024[428]. - Research and development expenses decreased by $10,388 to $13,791 for the year ended December 31, 2025, compared to $24,179 in 2024, mainly due to efficiency and post-merger integration activities[429]. - Sales and marketing expenses decreased by $6,012 to $20,338 for the year ended December 31, 2025, compared to $26,350 in 2024, attributed to lower payroll-related expenses[433]. - General and administrative expenses decreased by $5,291 to $15,191 for the year ended December 31, 2025, compared to $20,482 in 2024, mainly due to lower stock-based compensation and reduced acquisition costs[435]. - Net loss for the year ended December 31, 2025, was $41,714, a slight improvement from a net loss of $42,747 in 2024, primarily due to decreased operating expenses[441]. - Non-GAAP adjusted loss for the year ended December 31, 2025, was $24,152, an improvement from $33,792 in 2024, indicating better operational performance[452]. Cash Flow and Financing - The company had cash and cash equivalents of approximately $26,017 as of December 31, 2025, down from $28,461 at the end of 2024[454]. - The company has financed operations through private placements and public offerings, receiving aggregate net proceeds totaling $307,133 and a credit facility of $25,795 as of December 31, 2025[456]. - A five-year senior secured credit facility of up to $50 million was established with OrbiMed, with $25 million available at closing and an additional $25 million subject to revenue requirements[457]. - A four-year secured credit facility of up to $40,000 was entered into with Avenue Lenders, with $30,000 made available at closing[458]. - The company received gross proceeds of approximately $22,422 from the Series C Offering, which included the sale of 17,307 shares of Series C Preferred Stock[467]. - The company received gross proceeds of approximately $18,805 from the offering of Series D Preferred Stock, which included 7,055 shares of newly designated Series D Preferred Stock[468]. - The company entered into a securities purchase agreement for 1,154,420 shares of common stock and pre-funded warrants, generating approximately $17,500 in gross proceeds[487]. Debt and Covenants - The company did not meet a financial covenant under the Callodine Credit Agreement, leading to an Event of Default, with interest accruing at a rate of 3% over the Contract Rate[484]. - The Callodine Credit Agreement was amended to reset financial covenants and waive testing for the second and third quarters of 2025, with a new minimum cash covenant of $10 million[485]. - The Avenue Loan Facility includes interest rates that can reach up to 12.50% and additional fees for non-compliance with milestones[460]. Operational Challenges - The company has experienced cumulative losses since inception and expects to continue generating losses for the foreseeable future[455]. - The company had a U.S. federal net operating loss carryforward of approximately $47,055 as of December 31, 2025, which can be utilized against future taxable income[442]. - As of December 31, 2025, the company incurred an accumulated deficit of $452,078 and negative cash flows from operations of approximately $25,941 for the year[453][455]. - Net cash used in operating activities decreased to $25,941, a reduction from $38,562 in 2024, primarily due to decreased operating expenses and improved working capital[490]. - Net cash used for investing activities was $4,342 in 2025, down from $8,934 in 2024, reflecting the absence of significant acquisitions compared to the previous year[491]. - Net cash provided by financing activities was $24,313 in 2025, compared to $38,531 in 2024, with approximately $24,128 raised through offerings and $185 from refinancing[492]. Inventory and Supply Chain - Total inventory write-downs for the year ended December 31, 2025, amounted to $320, reflecting the company's focus on inventory and supply chain management[421].

Core Insights - DarioHealth Corp. will report its financial results for Q4 and full year 2025 on March 19, 2026, and will host a conference call at 8:30 a.m. Eastern Time [1] Company Overview - DarioHealth is a leader in the global digital health market, focusing on chronic condition management through a user-centric digital therapeutics platform [1] - The platform provides personalized interventions driven by data analytics and coaching for conditions such as diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health [1] - DarioHealth aims to disrupt traditional healthcare approaches by offering continuous and customized care, promoting sustainable behavior change and high user satisfaction [1] Conference Call Details - The conference call will feature CEO Erez Raphael, President Steven Nelson, and CFO Chen Franco-Yehuda [1] - Participants can join via dial-in numbers or a provided link for instant access, with a replay available after the call [1]

Core Insights - DarioHealth Corp. has published a study demonstrating significant blood glucose improvements among over 22,000 users of its platform, emphasizing the role of engagement in clinical outcomes [1][2] - The study utilized machine learning to analyze real-world data from 22,414 adults with type 2 diabetes, revealing distinct glycemic trajectories influenced by demographic, clinical, and engagement factors [1] - Higher digital engagement, particularly frequent blood glucose monitoring, was linked to more substantial and sustained glycemic improvements, with a threshold of 12 measurements per month identified as critical for positive outcomes [1] Company Overview - DarioHealth is a leading digital health company focused on transforming chronic condition management through a user-centric digital therapeutics platform [1] - The platform offers personalized interventions driven by data analytics and coaching for various health issues, including diabetes, hypertension, and weight management [1] - DarioHealth aims to provide continuous and customized care, moving away from traditional episodic healthcare approaches, thereby enhancing user satisfaction and retention [1] Research Findings - The study's findings indicate that engagement metrics serve as clinical signals that can impact return on investment (ROI) for employers and health plans [1] - Machine learning applications in the study allowed for the identification of user-specific responses and optimal intervention timing, enhancing personalized support for blood glucose management [1] - The research underscores Dario's capability to translate real-world data into measurable clinical impacts, making it a valuable partner for health plans and risk-bearing provider organizations [1]

Core Insights - DarioHealth is positioned to enhance the effectiveness of oral GLP-1 therapies through precision behavioral support, addressing the modest outcomes compared to injectable versions [1] - The demand for Dario's digital health solutions is increasing among employers and health plans, as they seek to improve medication adherence and health outcomes while managing costs [1] Group 1: Market Dynamics - Oral GLP-1 therapies are expected to capture 25% of the overall GLP-1 market, projected to reach $95 billion by 2030 [1] - The cost of GLP-1 medications is one of the fastest-growing expenses for payers, highlighting the need for effective behavioral support to optimize long-term health outcomes [1] Group 2: Dario's Solutions - 79% of members utilize Dario's weight management features within its integrated platform, showcasing the effectiveness of its structured behavioral reinforcement [1] - Dario's approach includes personalized coaching, a grocery scanner for better food choices, and a medication cabinet for adherence tracking, creating a comprehensive support system [1] Group 3: Behavioral Reinforcement - The company emphasizes that oral GLP-1s require stronger behavioral reinforcement to achieve optimal outcomes, as daily habits significantly impact treatment success [1] - Dario's solutions are designed to translate medication intentions into sustained actions, thereby enhancing the overall effectiveness of pharmacotherapy [1]

Core Insights - DarioHealth Corp. has surpassed 100 scientific studies, establishing itself as a trusted partner for organizations aiming to reduce costs and improve health outcomes in digital health delivery [1][2][3] Group 1: Research and Validation - The milestone of 100 studies places Dario among the top digital health vendors in terms of the volume and depth of scientifically reviewed evidence, which is increasingly demanded by self-insured employers and health plans [2][3] - Dario's research includes a significant number of independent, third-party investigator-initiated studies, showcasing a mature evidence base in digital health [3][8] - The studies feature large populations, longitudinal designs, and independent validations, demonstrating actual claims reduction and measurable health improvements rather than modeled results [8] Group 2: Value Proposition - Dario's user-centric platform offers continuous and customized care, promoting sustainable behavior change and exceptional user satisfaction [5][6] - The company’s approach disrupts traditional episodic healthcare, empowering individuals to manage chronic conditions effectively [4][5] - As healthcare purchasers shift towards value-based decision-making, Dario's expanding portfolio of peer-reviewed publications reinforces its role as an outcomes-driven partner capable of delivering measurable impact [3][4]